NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and certain senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's clinical trials and drug efficacy [2][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically through its investigational therapeutic sonelokimab (SLK) aimed at treating moderate to severe hidradenitis suppurativa [5]. Clinical Trials and Allegations - The company conducted Phase 3 VELA trials for sonelokimab, claiming strong clinical data and differentiation from competitors [6]. However, allegations suggest that the clinical data did not demonstrate superior benefits, raising doubts about the drug's regulatory approval and commercial viability [7]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share within a few days [8].

NEW YORK, Dec. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/moonlake-loss-submission-form/?id=179559&from=4CLASS PERIOD: March 10, 2024 t ...

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 15, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any upfront costs through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting that many firms may lack the necessary experience and resources [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the class period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, failing to disclose critical information about the product's clinical benefits [5]. - Specific claims include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's unique structure does not provide a clinical advantage over BIMZELX [5].

Core Viewpoint - The Gross Law Firm is notifying shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) about a class action lawsuit due to alleged misleading statements regarding the company's drug candidate SLK and its comparison to BIMZELX [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 10, 2024, to September 29, 2025, the defendants made materially false and/or misleading statements [3]. - Specific allegations include that SLK and BIMZELX share the same molecular targets, and SLK's unique Nanobody structure does not provide a clinical benefit over BIMZELX's traditional monoclonal structure [3]. - It is also claimed that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, indicating that the defendants lacked a reasonable basis for their positive statements about SLK's superiority [3]. Group 2: Class Action Details - Shareholders who purchased MLTX shares during the specified class period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 15, 2025 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, particularly related to the company's clinical trial results and claims about its investigational drug sonelokimab [2][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically through its investigational therapeutic sonelokimab [5]. Clinical Trials and Allegations - The company conducted Phase 3 VELA trials for sonelokimab, claiming strong clinical data and differentiation from competitors [6]. However, allegations suggest that the clinical data did not demonstrate a superior benefit over competitors, raising concerns about regulatory approval and commercial viability [7]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [8].

Core Viewpoint - The deadline for investors to apply for lead plaintiff status in the securities class action lawsuit against MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX) is December 15, 2025 [1] Group 1: Legal Context - The lawsuit focuses on whether the company's claims regarding its clinical study align with the actual clinical data received [1]

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, particularly related to the company's clinical data and the performance of its investigational drug sonelokimab [1][2][5]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses for patients and differentiation from competitors [4]. - Allegations suggest that the clinical data and the Nanobody structure of sonelokimab did not provide a superior clinical benefit, raising concerns about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Core Insights - Class actions have been initiated on behalf of stockholders of Cepton, Inc. and MoonLake Immunotherapeutics, with specific deadlines for investors to petition the court to serve as lead plaintiff [1] MoonLake Immunotherapeutics - The lawsuit alleges that MoonLake Immunotherapeutics misled investors regarding its drug candidate sonelokimab (SLK), claiming it was superior to competing monoclonal antibodies [6] - The complaint states that MoonLake and its executives promoted SLK's Nanobody structure as having unique clinical advantages while failing to disclose it targeted the same molecules as UCB's BIMZELX and had no proven superiority [6] - Following the announcement of Phase 3 results on September 28, 2025, which showed SLK did not match BIMZELX's efficacy, MoonLake's stock fell nearly 90%, resulting in significant investor losses [6] - On September 29, 2025, MoonLake filed a current report with the SEC indicating that intercurrent events in the higher-than-expected placebo arm prevented the study from achieving statistical significance [6] - The stock plummeted 89.9% on September 29, 2025, following this news [6] Cepton, Inc. - The lawsuit against Cepton alleges that defendants made materially false and misleading statements and failed to disclose tax fraud and bribery to cover it up [6] - The complaint claims that as a result of these actions, the legal risks facing the company were understated, leading to materially false and misleading statements about its business and operations [6] - Investors suffered damages when the true details of the situation became public [6]

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...